Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Sterling clings to gains vs euro in quiet day ahead of BoE meeting

Published 03/02/2021, 09:53
Updated 03/02/2021, 09:55
© Reuters. FILE PHOTO: Wads of British Pound Sterling banknotes are stacked in piles at the Money Service Austria company's headquarters in Vienna

By Joice Alves

LONDON (Reuters) - Sterling clung to gains against the euro on Wednesday but edged lower against the dollar on a quiet day as investors waited for Thursday's Bank of England meeting.

The pound has gained broadly in the past few weeks amid optimism over Britain's successful COVID-19 inoculation programme, with analysts pinning their hopes on a faster economic recovery than in the European Union, where vaccine rollout is lagging.

Market participants are focusing on the Bank of England's meeting on Thursday at which the central bank is set to publish the findings of a consultation on what negative rates would mean for banks' operations.

"I can see a fairly quiet day for sterling being on the cards given the magnitude of tomorrow's Bank of England meeting," said Simon Harvey, senior FX market analyst at Monex Europe in London.

Britain's third national coronavirus lockdown has put the economy on course for a sharp contraction in early 2021, but services companies - buoyed by progress on vaccinations - are confident about recovery, the final version of the IHS Markit/CIPS UK Composite Purchasing Managers' Index (PMI) showed.

With improved sentiment, most economists polled by Reuters said there is little chance the Bank of England will move to cut rates below zero this year.

In early London trading, sterling gained 0.1% versus the euro at 88.03 pence, not far from a eight-month high reached in the previous session against the single currency.

It was down 0.1% at $1.3650 versus a stronger dollar, after touching a one-week low against the greenback on Tuesday.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Health Secretary Matt Hancock said much of the attention need to be directed to any mutations of coronavirus that have been detected in recent days.

The COVID-19 vaccine developed by Oxford University and AstraZeneca gives good immune responses in older people, even if there is a lack of data about its exact efficacy, Oxford's vaccine trial chief Andrew Pollard said on Wednesday.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.